Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
ENDRA Life Sciences's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.
As of Mar. 2024, ENDRA Life Sciences has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
ENDRA Life Sciences Sloan Ratio % Historical Data
The historical data trend for ENDRA Life Sciences's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ENDRA Life Sciences's Sloan Ratio %
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Sloan Ratio % falls into.
ENDRA Life Sciences Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
ENDRA Life Sciences's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
ENDRA Life Sciences's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -2.557 (Jun. 2023 ) + -3.101 (Sep. 2023 ) + -1.46 (Dec. 2023 ) + -2.776 (Mar. 2024 ) = $-9.89 Mil.
ENDRA Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -2.269 (Jun. 2023 ) + -2.599 (Sep. 2023 ) + -2.175 (Dec. 2023 ) + -2.144 (Mar. 2024 ) = $-9.19 Mil.
ENDRA Life Sciences's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + -0.024 (Mar. 2024 ) = $-0.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (NAS:NDRAU) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, ENDRA Life Sciences has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
ENDRA Life Sciences Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of ENDRA Life Sciences's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRAU has been successfully added to your 